Organogenesis Holdings Inc [ORGO] stock prices are up 13.53% to $3.44 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ORGO shares have gain 29.32% over the last week, with a monthly amount drifted -35.58%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Organogenesis Holdings Inc [NASDAQ: ORGO] stock has seen the most recent analyst activity on June 28, 2024, when Lake Street initiated its Buy rating and assigned the stock a price target of $5. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on February 07, 2024, and set its price target to $5. On June 15, 2023, Morgan Stanley initiated with a Equal-Weight rating and assigned a price target of $5 on the stock. BTIG Research upgraded its rating to a Buy but stick to its price target of $10 on May 24, 2023. BTIG Research downgraded its rating to a Neutral. Oppenheimer downgraded its rating to Perform for this stock on August 10, 2022. In a note dated January 10, 2020, SVB Leerink initiated an Outperform rating and provided a target price of $9 on this stock.
The stock price of Organogenesis Holdings Inc [ORGO] has been fluctuating between $2.28 and $6.71 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Organogenesis Holdings Inc [NASDAQ: ORGO] shares were valued at $3.44 at the most recent close of the market. An investor can expect a potential return of 74.42% based on the average ORGO price forecast.
Analyzing the ORGO fundamentals
The Organogenesis Holdings Inc [NASDAQ:ORGO] reported sales of 458.76M for trailing twelve months, representing a drop of -21.17%. Gross Profit Margin for this corporation currently stands at 0.75% with Operating Profit Margin at -0.05%, Pretax Profit Margin comes in at -0.05%, and Net Profit Margin reading is -0.04%. To continue investigating profitability, this company’s Return on Assets is posted at -0.04, Equity is -0.06 and Total Capital is -0.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.29 points at the first support level, and at 3.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.65, and for the 2nd resistance point, it is at 3.86.
Ratios To Look Out For
It’s worth pointing out that Organogenesis Holdings Inc [NASDAQ:ORGO]’s Current Ratio is 4.12. As well, the Quick Ratio is 3.67, while the Cash Ratio is 1.69. Considering the valuation of this stock, the price to sales ratio is 0.95, the price to book ratio is 1.80.
Transactions by insiders
Recent insider trading involved Freedman Lori, Chief Admin. and Legal Officer, that happened on Jun 05 ’25 when 0.14 million shares were purchased. Chief Admin. and Legal Officer, Freedman Lori completed a deal on Jun 04 ’25 to buy 0.1 million shares. Meanwhile, Chief Admin. and Legal Officer Freedman Lori bought 9022.0 shares on Jun 06 ’25.
